Terms: = Colorectal cancer AND CDX2, CDX3, 1045, ENSG00000165556, Q99626 AND Prognosis
106 results:
1. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
[No Abstract] [Full Text] [Related]
2. ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer.
Fernandez-De-Los-Reyes I; Gomez-Dorronsoro M; Monreal-Santesteban I; Fernandez-Fernandez A; Fraga M; Azcue P; Alonso L; Fernandez-Marlasca B; Suarez J; Cordoba-Iturriagagoitia A; Guerrero-Setas D
Clin Epigenetics; 2023 Dec; 15(1):193. PubMed ID: 38093305
[TBL] [Abstract] [Full Text] [Related]
3. Multivariate Prognostic Models for Patients with Stages I and Ii Colon Carcinoma: a Strobe-Compliant Retrospective Cohort Study.
Oñate-Ocaña LF; Herrera-Goepfert R; Avilés-Salas A; Cortés CC; González-Trejo S; Carrillo JF; Ruiz-García E; Ochoa-Carrillo FJ; Aiello-Crocifoglio V; García-Cuellar CM
Rev Invest Clin; 2023; 75(5):259-271. PubMed ID: 37918013
[TBL] [Abstract] [Full Text] [Related]
4. The prognostic potential of cdx2 in colorectal cancer: Harmonizing biology and clinical practice.
Badia-Ramentol J; Gimeno-Valiente F; Duréndez E; Martínez-Ciarpaglini C; Linares J; Iglesias M; Cervantes A; Calon A; Tarazona N
Cancer Treat Rev; 2023 Dec; 121():102643. PubMed ID: 37871463
[TBL] [Abstract] [Full Text] [Related]
5. Loss of SATB2 and cdx2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
Li J; Zeng Q; Lin J; Huang H; Chen L
Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
[TBL] [Abstract] [Full Text] [Related]
6. cdx2 Is a Prognostic Biomarker for Unresectable Metastatic colorectal cancer.
Mukohyama J; Agawa K; Yamashita K; Matsuda T; Shinoda M; Itano O; Kakeji Y
Anticancer Res; 2023 Aug; 43(8):3763-3767. PubMed ID: 37500172
[TBL] [Abstract] [Full Text] [Related]
7. Deciphering Brain Metastasis Stem Cell Properties From colorectal cancer Highlights Specific Stemness Signature and Shared Molecular Features.
Desette A; Guichet PO; Emambux S; Masliantsev K; Cortes U; Ndiaye B; Milin S; George S; Faigner M; Tisserand J; Gaillard A; Brot S; Wager M; Tougeron D; Karayan-Tapon L
Cell Mol Gastroenterol Hepatol; 2023; 16(5):757-782. PubMed ID: 37482243
[TBL] [Abstract] [Full Text] [Related]
8. Pattern of expression of cdx2 in colorectal cancer and its role in prognosis.
Singh J; Rajesh NG; Dubashi B; Maroju NK; Ganesan P; Matta KK; Charles I; Kayal S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S420-S427. PubMed ID: 36510997
[TBL] [Abstract] [Full Text] [Related]
9. Immunohistochemical analysis of the distribution of RANKL: a case of disseminated carcinomatosis of bone marrow as the first presentation of relapse in curatively resected colorectal cancer.
Shimada Y; Nagaba Y; Okawa H; Ehara K; Okada S; Naito M; Yokomori H
Med Mol Morphol; 2023 Jun; 56(2):138-143. PubMed ID: 36478259
[TBL] [Abstract] [Full Text] [Related]
10. cdx2 as a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis through EMT in colorectal cancer.
Wang YS; Kou Y; Zhu RT; Han BW; Li CH; Wang HJ; Wu HB; Xia TM; Che XM
Dis Markers; 2022; 2022():9025668. PubMed ID: 36277982
[TBL] [Abstract] [Full Text] [Related]
11. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract] [Full Text] [Related]
12. Combination of cdx2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
Derangère V; Lecuelle J; Lepage C; Aoulad-Ben Salem O; Allatessem BM; Ilie A; Bouché O; Phelip JM; Baconnier M; Pezet D; Sebbagh V; Terrebonne E; Bouard G; Jooste V; Bouvier AM; Molimard C; Monnien F; Gonzalez D; Le Malicot K; Rageot D; Truntzer C; Bibeau F; Ghiringhelli F;
Eur J Cancer; 2022 Sep; 172():221-230. PubMed ID: 35785606
[TBL] [Abstract] [Full Text] [Related]
13. The Complete Loss of p53 Expression Uniquely Predicts Worse prognosis in colorectal cancer.
Nagao K; Koshino A; Sugimura-Nagata A; Nagano A; Komura M; Ueki A; Ebi M; Ogasawara N; Tsuzuki T; Kasai K; Takahashi S; Kasugai K; Inaguma S
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328677
[TBL] [Abstract] [Full Text] [Related]
14. Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon cancer.
Chen K; Wang H; Collins G; Hollands E; Law IYJ; Toh JWT
Curr Oncol; 2022 Feb; 29(3):1370-1389. PubMed ID: 35323316
[TBL] [Abstract] [Full Text] [Related]
15. cdx2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer.
Delhorme JB; Bersuder E; Terciolo C; Vlami O; Chenard MP; Martin E; Rohr S; Brigand C; Duluc I; Freund JN; Gross I
Biomed Pharmacother; 2022 Mar; 147():112630. PubMed ID: 35051860
[TBL] [Abstract] [Full Text] [Related]
16. [A Case of Multiple Hepatic Metastases after Surgery for Low Differentiated Mucous cancer of Sigmoid Colon with Notable Mesenteric Infiltration in Which Chemotherapy Was Effective].
Tani H; Takaishi H; Ihara T; Murakami D; Aratake K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2155-2157. PubMed ID: 35045523
[TBL] [Abstract] [Full Text] [Related]
17. Pathological Features and Prognostication in colorectal cancer.
Chen K; Collins G; Wang H; Toh JWT
Curr Oncol; 2021 Dec; 28(6):5356-5383. PubMed ID: 34940086
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, cdx2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
Aasebø K; Bruun J; Bergsland CH; Nunes L; Eide GE; Pfeiffer P; Dahl O; Glimelius B; Lothe RA; Sorbye H
Br J Cancer; 2022 Jan; 126(1):48-56. PubMed ID: 34671130
[TBL] [Abstract] [Full Text] [Related]
19. Loss of CDX-2 expression is an independent poor prognostic biomarker in patients with early-stage deficient mismatch repair colorectal cancer.
Korphaisarn K; Sukhokanjanachusak K; Pongpaibul A; Chinswangwatanakul V; Akewanlop C
Asia Pac J Clin Oncol; 2022 Jun; 18(3):249-258. PubMed ID: 34161647
[TBL] [Abstract] [Full Text] [Related]
20. Outcomes and Prognostic Factors of Patients with Metastatic colorectal cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience.
Gössling GCL; Chedid MF; Pereira FS; da Silva RK; Andrade LB; Peruzzo N; Saueressig MG; Schwartsmann G; Parikh AR
Oncologist; 2021 Sep; 26(9):e1581-e1588. PubMed ID: 33896091
[TBL] [Abstract] [Full Text] [Related]
[Next]
